Immunohematology Section, Tor Vergata University and SIMT Bambino Gesù Pediatric Hospital, Rome, Italy.
Cytotherapy. 2010;12(1):60-6. doi: 10.3109/14653240903348301.
Immunomagnetic CD34(+) cell selection (ICS) is utilized in autologous and allogeneic transplants. In the first case it is used to reduce the neoplastic contamination of concentrates, while in the second case it is needed to carry out a T-depletion of cell concentrates in order to reduce the incidence of graft-versus-host disease (GvHD) in patients who have undergone haplo-identical transplants.
The efficacy of CliniMACS technology, after reduction of platelet contamination, incubation of monoclonal antibodies (MAb) and successive washings of concentrates, performed in 16 ICS using the standard method without reducing platelet content, was compared with the use of the automated system CytoMate, which was carried out in 46 ICS.
In the group of ICS carried out after automatic manipulation, a significant statistical difference in purity was noted (91.39% versus 83.57, P = 0.017) compared with the group of ICS carried out with the standard procedure. The same significant difference was noted in relation to the remaining percentages of CD3(+) and CD19(+) cells (2.31% versus 5.68%, P = 0.012, and 1.58% versus 2.71%, P = 0.014, respectively). Recovery of CD34+ cells overlapped in the two groups (70.49% versus 68.39%, P = 0.774).
Immunomagnetic selection carried out using the automated procedure was more efficient, producing a purer sample, more efficient T-depletion and optimal reduction of B cells, without influencing cell recovery. Furthermore, conforming to good manufacturing practice (GMP) guidelines, the entire procedure with CytoMate took place in a contamination-controlled environment.
免疫磁珠 CD34(+)细胞分选(ICS)用于自体和同种异体移植。在前者中,它用于减少浓缩物中的肿瘤污染,而在后者中,需要对细胞浓缩物进行 T 细胞耗竭,以降低接受半相合移植的患者发生移植物抗宿主病(GvHD)的发生率。
比较了在 16 例 ICS 中采用标准方法(不减少血小板含量)和在 46 例 ICS 中采用自动化系统 CytoMate 进行操作时,减少血小板污染、孵育单克隆抗体(MAb)和连续洗涤浓缩物后,CliniMACS 技术的疗效。
在自动操作的 ICS 组中,与采用标准程序的 ICS 组相比,纯度有显著的统计学差异(91.39% 与 83.57%,P=0.017)。与剩余的 CD3(+)和 CD19(+)细胞百分比(分别为 2.31%与 5.68%,P=0.012,和 1.58%与 2.71%,P=0.014)相比,也有显著差异。两组间 CD34+细胞的回收率重叠(70.49% 与 68.39%,P=0.774)。
使用自动化程序进行免疫磁珠分选更有效,产生更纯净的样本,T 细胞耗竭更有效,B 细胞的最佳减少,而不影响细胞回收。此外,由于符合良好生产规范(GMP)指南,整个 CytoMate 过程都在污染控制环境中进行。